BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32840404)

  • 1. Therapeutic vaccines for aggressive B-cell lymphoma.
    Xu-Monette ZY; Young KH
    Leuk Lymphoma; 2020 Dec; 61(13):3038-3051. PubMed ID: 32840404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
    Abramson JS
    Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
    Yamamoto M; Watanabe K; Fukuda T; Miura O
    Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?
    Ngu H; Takiar R; Phillips T; Okosun J; Sehn LH
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-14. PubMed ID: 35594501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic developments and advances in B-cell lymphoma].
    Miyazaki K
    Rinsho Ketsueki; 2022; 63(6):619-625. PubMed ID: 35831197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma.
    Zhao F; Qin Y; Yang J; Liu P; He X; Zhou L; Zhou S; Gui L; Zhang H; Wang X; Jiang S; Zhong Q; Zhou Y; Shi Y
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):385-391. PubMed ID: 32779387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma.
    Camus V; Tilly H
    Expert Rev Hematol; 2017 Dec; 10(12):1047-1055. PubMed ID: 27791447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Kang HJ; Lee HH; Jung SE; Park KS; O JH; Jeon YW; Choi BO; Cho SG
    PLoS One; 2020; 15(9):e0238807. PubMed ID: 32960887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
    Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
    Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
    Zhou N; Choi J; Grothusen G; Kim BJ; Ren D; Cao Z; Liu Y; Li Q; Inamdar A; Beer T; Tang HY; Perkey E; Maillard I; Bonasio R; Shi J; Ruella M; Wan L; Busino L
    Blood; 2023 Sep; 142(11):973-988. PubMed ID: 37235754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review.
    Jin X; Liu H; Li J; Xiao X; Yuan X; Chen P; Chen B; Liang Y; Huang F
    J Zhejiang Univ Sci B; 2023 Aug; 24(8):711-722. PubMed ID: 37551557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
    Epperla N; Kumar A; Abutalib SA; Awan FT; Chen YB; Gopal AK; Holter-Chakrabarty J; Kekre N; Lee CJ; Lekakis L; Lin Y; Mei M; Nathan S; Nastoupil L; Oluwole O; Phillips AA; Reid E; Rezvani AR; Trotman J; Zurko J; Kharfan-Dabaja MA; Sauter CS; Perales MA; Locke FL; Carpenter PA; Hamadani M
    Transplant Cell Ther; 2023 Sep; 29(9):548-555. PubMed ID: 37419325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL.
    Lim SK; Peng CC; Low S; Vijay V; Budiman A; Phang BH; Lim JQ; Jeyasekharan AD; Lim ST; Ong CK; Tan SM; Li Y
    Leukemia; 2023 Feb; 37(2):441-452. PubMed ID: 36446947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment approaches for diffuse large B-cell lymphoma].
    Miyazaki K; Yamaguchi M
    Nihon Rinsho; 2014 Mar; 72(3):483-7. PubMed ID: 24724408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.